
|Articles|November 19, 2012
KalVista wins grant for DME treatment
KalVista Pharmaceuticals has received a £2.4 million grant to accelerate development of an oral plasma kallikrein inhibitor for the treatment of diabetic macular edema.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Ophthalmology pipeline watch: Key trial results and PDUFA dates for Q1 2026
2
Ocugen publishes phase 1 GARDian1 gene therapy data for Stargardt disease
3
Ocugen releases positive preliminary 12-month data from phase 2 ArMaDa trial
4
Rayner announces Sophi Phaco System in the US
5














































